retatrutide sleep apnea Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Lilly's GLP-1/GIP tirzepatide clears sleep

These support satiety and steadier blood sugar, and they fit well with how GLP-1 medications change appetite

In the cardiovascular system, atherosclerosis becomes apparent as the invisible killer. Atherosclerosis causes cerebral ischemia, or angina pectoris, with the development of atherosclerotic plaques

Second, as the main analysis, we used a per-protocol approach to estimate the increased risk of SIS in GLP-1RA vs SGLT-2i users

Finally, although most of the evidence of a potential benefit of GLP-1 RAs in HF originates from CVOTs in type 2 diabetes, it may likely be in the weight management setting that the drug class could be of the highest clinical value, particularly in people with HFpEF